Drug-drug interaction discovery and demystification using Semantic Web technologies

被引:24
作者
Noor, Adeeb [1 ]
Assiri, Abdullah [2 ,3 ]
Ayvaz, Serkan [4 ]
Clark, Connor
Dumontier, Michel [5 ]
机构
[1] King Abdulaziz Univ, Fac Comp & Informat Technol, Jeddah, Saudi Arabia
[2] Purdue Univ, Sch Pharm, W Lafayette, IN 47907 USA
[3] King Khalid Univ, Sch Pharm, Abha, Saudi Arabia
[4] Bahcesehir Univ, Dept Comp Engn, TR-34353 Istanbul, Turkey
[5] Stanford Ctr Biomed Informat Res, Stanford, CA USA
关键词
drug interactions; pharmacovigilance; pharmacologic actions; Semantic Web; COLORECTAL-CANCER; P-GLYCOPROTEIN; CYTOCHROME-P450; EVENTS; PHARMACOMETRICS; TERMINOLOGY; INFORMATION; DISPOSITION; METABOLISM; IBUPROFEN;
D O I
10.1093/jamia/ocw128
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Objective: To develop a novel pharmacovigilance inferential framework to infer mechanistic explanations for asserted drug-drug interactions (DDIs) and deduce potential DDIs. Materials and Methods: A mechanism-based DDI knowledge base was constructed by integrating knowledge from several existing sources at the pharmacokinetic, pharmacodynamic, pharmacogenetic, and multipathway interaction levels. A query-based framework was then created to utilize this integrated knowledge base in conjunction with 9 inference rules to infer mechanistic explanations for asserted DDIs and deduce potential DDIs. Results: The drug-drug interactions discovery and demystification (D3) system achieved an overall 85% recall rate in terms of inferring mechanistic explanations for the DDIs integrated into its knowledge base, while demonstrating a 61% precision rate in terms of the inference or lack of inference of mechanistic explanations for a balanced, randomly selected collection of interacting and noninteracting drug pairs. Discussion: The successful demonstration of the D3 system's ability to confirm interactions involving well-studied drugs enhances confidence in its ability to deduce interactions involving less-studied drugs. In its demonstration, the D3 system infers putative explanations for most of its integrated DDIs. Further enhancements to this work in the future might include ranking interaction mechanisms based on likelihood of applicability, determining the likelihood of deduced DDIs, and making the framework publicly available. Conclusion: The D3 system provides an early-warning framework for augmenting knowledge of known DDIs and deducing unknown DDIs. It shows promise in suggesting interaction pathways of research and evaluation interest and aiding clinicians in evaluating and adjusting courses of drug therapy.
引用
收藏
页码:556 / 564
页数:9
相关论文
共 50 条
[31]   Pharmacokinetic drug-drug interaction and their implication in clinical management [J].
Caterina, Palleria ;
Antonello, Di Paolo ;
Chiara, Giofre ;
Chiara, Caglioti ;
Giacomo, Leuzzi ;
Antonio, Siniscalchi ;
Giovambattista, De Sarro ;
Luca, Gallelli .
JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2013, 18 (07) :600-609
[32]   Cobicistat: A case of mislabelled drug-drug interaction risk? [J].
Burger, David M. ;
Calmy, Alexandra ;
Marzolini, Catia .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (05) :834-836
[33]   Assessment tool for pharmacy drug-drug interaction software [J].
Warholak, Terri L. ;
Hines, Lisa E. ;
Saverno, Kim R. ;
Grizzle, Amy J. ;
Malone, Daniel C. .
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2011, 51 (03) :418-424
[34]   Amiodarone Rifampicin Drug-Drug Interaction Management With Therapeutic Drug Monitoring [J].
Munnink, Thijs H. Oude ;
Demmer, Anna ;
Slenter, Roel H. J. ;
Movig, Kris L. L. .
THERAPEUTIC DRUG MONITORING, 2018, 40 (02) :159-161
[35]   Studying the right transporter at the right time: an in vitro strategy for assessing drug-drug interaction risk during drug discovery and development [J].
Elsby, Robert ;
Atkinson, Hayley ;
Butler, Philip ;
Riley, Robert J. .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2022, 18 (10) :619-655
[36]   Drug-Drug Interaction between Anaesthetic Drug Propofol and Andrographolide Derivative [J].
Li, Ming-Chuan ;
Pan, Wei-Zhong ;
Wang, Gao ;
Li, Zhi ;
Ma, Jia-Hai ;
Li, Ke-Zhong ;
Shi, Cun-Xian .
LATIN AMERICAN JOURNAL OF PHARMACY, 2015, 34 (08) :1688-1692
[37]   Pharmacokinetic Drug-Drug Interaction of Calcium Channel Blockers With Cyclosporine in Hematopoietic Stem Cell Transplant Children [J].
Bernard, Elodie ;
Goutelle, Sylvain ;
Bertrand, Yves ;
Bleyzac, Nathalie .
ANNALS OF PHARMACOTHERAPY, 2014, 48 (12) :1580-1584
[38]   Recommendations to improve the usability of drug-drug interaction clinical decision support alerts [J].
Payne, Thomas H. ;
Hines, Lisa E. ;
Chan, Raymond C. ;
Hartman, Seth ;
Kapusnik-Uner, Joan ;
Russ, Alissa L. ;
Chaffee, Bruce W. ;
Hartman, Christian ;
Tamis, Victoria ;
Galbreth, Brian ;
Glassman, Peter A. ;
Phansalkar, Shobha ;
van der Sijs, Heleen ;
Gephart, Sheila M. ;
Mann, Gordon ;
Strasberg, Howard R. ;
Grizzle, Amy J. ;
Brown, Mary ;
Kuperman, Gilad J. ;
Steiner, Chris ;
Sullins, Amanda ;
Ryan, Hugh ;
Wittie, Michael A. ;
Malone, Daniel C. .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2015, 22 (06) :1243-1250
[39]   Evaluation of usage patterns and user perception of the drug-drug interaction database SFINX [J].
Andersson, Marine L. ;
Bottiger, Ylva ;
Bastholm-Rahmner, Pia ;
Ovesjo, Marie-Louise ;
Veg, Aniko ;
Eiermann, Birgit .
INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2015, 84 (05) :327-333
[40]   Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study [J].
Letinier, Louis ;
Cossin, Sebastien ;
Mansiaux, Yohann ;
Arnaud, Mickael ;
Salvo, Francesco ;
Bezin, Julien ;
Thiessard, Frantz ;
Pariente, Antoine .
FRONTIERS IN PHARMACOLOGY, 2019, 10